Anti-obesity combination therapy of enavogliflozin and low-dose liraglutide
MX2026008042APending Publication Date: 2026-10-02DAEWOONG PHARM CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MX2026008042
- Authority / Receiving Office
- MX · MX
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-27
- Filing Date
- 2026-06-25
- Publication Date
- 2026-10-02
Abstract
The present invention provides an obesity treatment therapy with reduced side effects through co-administration of enavogliflozin and low-dose liraglutide. The combination therapy of enavogliflozin and low dose liraglutide provides a synergistic effect in the treatment of obesity compared to the administration of each drug alone. In addition, the administration dose of liraglutide can be reduced compared to the administration of liraglutide alone, thereby reducing the liraglutide-associated direct cause of side effects related to the gastrointestinal and cardiovascular systems. In addition, the present invention has an advantage of additionally providing an effect of alleviating metabolic diseases and cardiovascular diseases related to blood glucose, blood lipids, blood pressure, fatty liver, and the like through the combination with enavogliflozin.
Need to check novelty before this filing date? Find Prior Art
